Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
SynBioVen is a venture capital firm established in early 2022, located in the United Kingdom. The firm is dedicated to supporting synthetic biology scientists, founders, and startups, operating under the belief that synthetic biology will significantly contribute to the next industrial revolution and the transition to a net-zero economy. Since its inception, SynBioVen has focused on early-stage investments, particularly in the pre-seed and seed stages, to foster innovation in this critical sector.
As of now, SynBioVen manages a portfolio of seven companies, showcasing its commitment to the biotech and healthcare sectors. The firm collaborates with notable organizations such as SynbiCITE and the London Biofoundry, providing startups with access to essential resources and expertise. This collaboration enhances their ability to support ventures that aim to address environmental challenges through synthetic biology.
SynBioVen's strategic focus on early-stage investments positions it as a key player in the UK biotech ecosystem, aiming to drive advancements that align with sustainability goals. The firm is actively building its presence and reputation in the synthetic biology sector, making it an attractive partner for startups looking to innovate.
SynBioVen invests primarily in early-stage synthetic biology ventures, specifically targeting pre-seed and seed funding rounds. The firm provides proof of concept (PoC) funding, which is crucial for startups looking to validate their innovative ideas. Their investment strategy emphasizes supporting companies that contribute to environmental sustainability and the next industrial revolution.
The organization offers access to a wealth of expertise in synthetic biology research, business development, and financing. This support is further enhanced by their R&D Hub located in West London, which facilitates collaboration with SynbiCITE and provides access to the London Biofoundry. SynBioVen seeks to partner with founders who are passionate about leveraging synthetic biology to create impactful solutions in the biotech and healthcare sectors.
In terms of deal structure, SynBioVen is open to various arrangements that align with their mission of fostering innovation in synthetic biology. They prioritize ventures that demonstrate a clear potential for addressing pressing environmental challenges and advancing industrial processes.
SynBioVen's portfolio consists of seven innovative companies that exemplify the potential of synthetic biology. Notable portfolio companies include:
These companies reflect SynBioVen's commitment to investing in ventures that not only advance synthetic biology but also address significant environmental and health challenges.
Sir David Harding: Founder and CEO of SynBioVen, Sir David has extensive experience in investment and entrepreneurship, particularly in the biotech sector.
Lord David Willetts FRS: Former UK Minister for Universities and Science, Lord Willetts brings a wealth of knowledge in policy and academia, enhancing SynBioVen's strategic direction.
Prof Richard Kitney OBE: Co-founder of the Imperial College Synthetic Biology Cluster, Prof Kitney is an expert in synthetic biology and engineering, providing valuable insights into the field.
Prof Paul Freemont: Also a co-founder of the Imperial College Synthetic Biology Cluster, Prof Freemont specializes in synthetic biology and its applications, contributing to SynBioVen's investment thesis.
To pitch SynBioVen, founders should reach out through their official website. A well-structured pitch deck should include an overview of the business model, market analysis, and details on how the venture contributes to sustainability. SynBioVen prefers to receive pitches via email or through their website contact form. Response times may vary, but founders can expect to hear back within a few weeks.
Since its founding in early 2022, SynBioVen has been actively building its portfolio in the synthetic biology sector. The firm has successfully invested in seven companies, demonstrating its commitment to early-stage ventures. Collaborations with SynbiCITE and the London Biofoundry have been established to enhance support for startups in this field.
As of October 2023, SynBioVen continues to seek new investment opportunities within the UK, focusing on innovative startups that align with their mission of sustainability and environmental impact.
What investment criteria does SynBioVen look for?
SynBioVen focuses on early-stage synthetic biology ventures that demonstrate innovative solutions with potential environmental benefits. They prioritize companies in the biotech and healthcare sectors that align with their mission of sustainability.
How can I apply or pitch to SynBioVen?
Founders interested in pitching to SynBioVen should prepare a detailed presentation that outlines their business model, market potential, and how their venture contributes to sustainability. Direct inquiries can be made through their website.
What makes SynBioVen different from other investors?
SynBioVen distinguishes itself by its exclusive focus on synthetic biology and its commitment to supporting early-stage ventures with proof of concept funding. Their collaboration with SynbiCITE and access to the London Biofoundry provides unique resources for portfolio companies.
What is SynBioVen's geographic scope?
SynBioVen primarily invests in the United Kingdom, focusing on local startups that are innovating in the synthetic biology space.
What is the typical check size for investments?
While specific check sizes are not disclosed, SynBioVen typically invests in pre-seed and seed rounds, which generally range from tens of thousands to a few million pounds, depending on the startup's needs and potential.
What kind of post-investment involvement does SynBioVen have?
SynBioVen actively supports its portfolio companies through access to expertise in synthetic biology, business development, and financing, as well as collaboration opportunities within their R&D Hub.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.